Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
about
Updates on cardiovascular outcome trials in diabetes.GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk.The CANTOS Trial: One Important Step for Clinical Cardiology but a Giant Leap for Vascular Biology.Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial).Soluble Urokinase Plasminogen Activator Receptor and the Risk of Coronary Artery Disease in Young Chinese Patients.Efferocytosis and Outside-In Signaling by Cardiac Phagocytes. Links to Repair, Cellular Programming, and Intercellular Crosstalk in Heart.The heart matters in diabetes: 10-Year outcomes of peripheral artery disease.Inflammation and atherosclerosis: fulfilling Koch's postulates.Colors of Myocardial Infarction: Can They Predict the Future?Can Biomarkers Advance HIV Research and Care in the ART Era?Pretenders and Contenders: Inflammation, C-Reactive Protein, and Interleukin-6.Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial.Hypercholesterolemia Enhances T Cell Receptor Signaling and Increases the Regulatory T Cell Population.Transcriptome-wide association study of inflammatory biologic age.Moderate-to-severe atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity.The use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis: does targeting inflammatory pathways with a treatment lead to vascular toxicity?Detection of circulating natural antibodies to inflammatory cytokines in type-2 diabetes and clinical significance.Implication of Free Fatty Acids in Thrombin Generation and Fibrinolysis in Vascular Inflammation in Zucker Rats and Evolution with Aging.Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis.Exploring immune checkpoints as potential therapeutic targets in atherosclerosis.The Gasdermin-D pore acts as a conduit for IL-1β secretion in mice.Redundancy and robustness versus division of labour and specialization in innate immunity.Overview of the IL-1 family in innate inflammation and acquired immunity.Macrophages under pressure: the role of macrophage polarization in hypertension.Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation.TNF Antagonists: Killing Two "Birds" with one Biologic "Stone".Inflammatory Biomarkers of Cardiometabolic Risk in Obese Egyptian Type 2 Diabetics.What's coming for health science and policy in 2018? Global experts look ahead in their field.The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC.Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond.Attenuation of Myeloid-Specific TGFβ Signaling Induces Inflammatory Cerebrovascular Disease and Stroke.Monocyte-Macrophages and T Cells in Atherosclerosis.Interleukin 1 gene polymorphism and susceptibility to disease.Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities.Anti-inflammatory Nanomedicine for Cardiovascular Disease.Genetic Support for a Causal Role of Insulin Resistance on Circulating Branched-Chain Amino Acids and Inflammation.Evolving Role of Non-Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future.Canakinumab for secondary prevention of atherosclerotic disease.A COMPASS to REACH the right patients with thrombocardiology: benefits, risks, and future of the new concept.A spotlight on the management of complications associated with myeloproliferative neoplasms: a clinician's perspective.
P2860
Q42375211-0936A6FC-FF69-47A1-85A4-07E74A60DC0CQ42617646-8BF393A2-5D25-4B91-AAFE-937EE411670BQ45069046-86602D69-29BE-4A5D-975C-6CB087124D55Q45073053-44A5D677-AADD-44D9-9006-ED53238BC8BDQ45306072-07793F2E-2966-406D-816D-383CAB9F4FA0Q45341410-3239607D-2DB2-4182-8696-E153ADB22758Q46019677-AE8D8B35-16A8-46BD-84C4-D7A2C6A214D9Q46176345-B304D1AF-160B-4EC6-8F87-73BE152E52DEQ46355205-663760BD-775A-47AA-825F-2DE347938A01Q46442340-52C53A44-CB9F-4112-8814-B9A49D0B1EE9Q47098515-B582F84F-3A8E-41EC-BF0B-AB9603667572Q47106217-42585038-39F0-41DC-9662-F24CC9EA7A66Q47107304-20F1B70E-30B0-4543-B7C7-EAC05FD023D8Q47113354-B1DEBE81-8DE9-4998-B222-7D7D08E4BA2FQ47120280-ED051A6E-C7F2-42C0-ABC6-06939543296EQ47159332-AAD00AC4-BD75-40FE-B0BF-1CE1DD38BBFBQ47159877-F470B354-1200-4DDD-B1BB-745086642EEAQ47169231-0B048A41-BBAD-4237-8041-2F3A6B462D24Q47218445-2A7921E5-289C-4A67-A193-65260D9D5889Q47224948-701AD568-C68F-47FB-BB6A-5AC054CB80A7Q47258910-BD54CC84-2456-40B7-A638-75A9954CC577Q47259971-5BC02356-C01B-4924-A12B-119D1B55B142Q47285878-9D3D406F-2001-4409-8034-2F047F62CE79Q47368141-2B6C0295-741D-457F-A4D3-09948131EC7BQ47394637-20603DF0-6560-4FA2-8C20-0D2368BA655DQ47395275-393F40E3-CDCD-4507-8033-1A9BE238089CQ47445962-C29343AB-A465-4498-B3EB-E4301FF4C9AEQ47551742-364F6F56-B45C-47E9-A690-A60CDF23E508Q47553695-E0A54D02-7FD5-46B3-AFE3-44278D31DCD1Q47599422-CB8B2807-4DB8-4BAB-8B7B-154F5ED88186Q47626596-59E79CEC-5B74-409C-AEAB-A2B0E85D4104Q47632654-B0E4CB8D-216F-4DDA-8617-A7ACB770AED0Q47653353-3C93EDDD-5A68-4AA0-9424-74929157D9E9Q47704613-FD275BEF-1A10-4EB0-A4EF-27B935CFC84FQ47744781-F48B7AEF-65B9-4FFC-933A-1BF416451BD4Q47766312-9D371821-7567-4AE0-A6FA-A6DF9B80EB95Q47769899-92E9ED9C-86B2-4E8A-992C-96EC1A8916AAQ47770079-B54EEC4D-5CCC-419E-A54D-323CBBE30520Q47779977-2FDC771F-BEB1-44EA-97F4-3A74E48EEFA0Q47813570-E8080745-BC6E-43A9-B535-75CF46293E2C
P2860
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
@en
type
label
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
@en
prefLabel
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
@en
P2093
P50
P356
P1476
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
@en
P2093
Alberto Lorenzatti
Brendan M Everett
CANTOS Trial Group
Christie Ballantyne
Daniel Pella
Francisco Fonseca
Hiroaki Shimokawa
Hisao Ogawa
Jan H Cornel
Jean G MacFadyen
P356
10.1056/NEJMOA1707914
P407
P577
2017-08-27T00:00:00Z